{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T15:23:53Z","timestamp":1789140233021,"version":"build-2803163510"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T00:00:00Z","timestamp":1718236800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology Cardiovascular Risk and Prevention"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.ijcrp.2024.200298","type":"journal-article","created":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T03:59:41Z","timestamp":1718423981000},"page":"200298","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Efficacy and safety of drugs in residual cardiovascular risk: A systematic review of the literature"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1678-3049","authenticated-orcid":false,"given":"Mario Andres","family":"Hernandez-S\u00f3merson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Montoya-Agudelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo","family":"Huertas-Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcrp.2024.200298_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2022.100371","article-title":"There is urgent need to treat atherosclerotic cardiovascular disease risk earlier, more intensively, and with greater precision: a review of current practice and recommendations for improved effectiveness","volume":"12","author":"Makover","year":"2022","journal-title":"Am. J. Prev. Cardiol."},{"key":"10.1016\/j.ijcrp.2024.200298_bib2","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2020.00088","article-title":"The evolving understanding and approach to residual cardiovascular risk management","volume":"7","author":"Dhindsa","year":"2020","journal-title":"Front. Cardiovasc. Med."},{"issue":"suppl_C","key":"10.1016\/j.ijcrp.2024.200298_bib3","doi-asserted-by":"crossref","first-page":"C2","DOI":"10.1093\/eurheartj\/suw009","article-title":"Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia","volume":"18","author":"Ferrari","year":"2016","journal-title":"Eur. Heart J. Suppl."},{"key":"10.1016\/j.ijcrp.2024.200298_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2019.00016","article-title":"Targeting residual inflammatory risk: a shifting paradigm for atherosclerotic disease","volume":"6","author":"Aday","year":"2019","journal-title":"Front. Cardiovasc. Med."},{"issue":"2","key":"10.1016\/j.ijcrp.2024.200298_bib5","doi-asserted-by":"crossref","DOI":"10.1038\/s41569-021-00654-w","article-title":"Inflammation in plaque erosion and rupture","volume":"19","author":"Huynh","year":"2022","journal-title":"Nat. Rev. Cardiol."},{"issue":"6","key":"10.1016\/j.ijcrp.2024.200298_bib6","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1177\/1074248418778548","article-title":"The utility of anti\u2013inflammatory agents in cardiovascular disease","volume":"23","author":"Kottoor","year":"2018","journal-title":"J. Cardiovasc. Pharmacol. Therapeut."},{"issue":"2","key":"10.1016\/j.ijcrp.2024.200298_bib7","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.acvd.2020.11.006","article-title":"Triglycerides and risk of atherosclerotic cardiovascular disease: an update","volume":"114","author":"Farnier","year":"2021","journal-title":"Arch. Cardiovasc. Dis."},{"issue":"6","key":"10.1016\/j.ijcrp.2024.200298_bib8","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s10557-019-06906-9","article-title":"Lipoprotein(a) and atherosclerotic cardiovascular disease: current understanding and future perspectives","volume":"33","author":"Wu","year":"2019","journal-title":"Cardiovasc. Drugs Ther."},{"issue":"3","key":"10.1016\/j.ijcrp.2024.200298_bib9","first-page":"26","article-title":"Vulnerable plaque, characteristics, detection, and potential therapies","volume":"6","author":"Hafiane","year":"2019","journal-title":"J. Cardiovasc. Dev. Dis."},{"issue":"1","key":"10.1016\/j.ijcrp.2024.200298_bib10","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41572-019-0106-z","article-title":"Atherosclerosis","volume":"5","author":"Libby","year":"2019","journal-title":"Nat. Rev. Dis. Prim."},{"issue":"1","key":"10.1016\/j.ijcrp.2024.200298_bib11","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with Icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"22","key":"10.1016\/j.ijcrp.2024.200298_bib12","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1001\/jama.2020.22258","article-title":"Effect of high\u2013dose omega\u20133 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk","volume":"324","author":"Nicholls","year":"2020","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.ijcrp.2024.200298_bib13","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1161\/CIRCULATIONAHA.118.034309","article-title":"Clinical benefit of evolocumab by severity and extent of coronary artery disease","volume":"138","author":"Sabatine","year":"2018","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.ijcrp.2024.200298_bib14","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","article-title":"Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk","volume":"139","author":"O'Donoghue","year":"2019","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.ijcrp.2024.200298_bib15","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jacc.2012.10.027","article-title":"Low\u2013dose colchicine for secondary prevention of cardiovascular disease","volume":"61","author":"Nidorf","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"issue":"19","key":"10.1016\/j.ijcrp.2024.200298_bib16","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","article-title":"Colchicine in patients with chronic coronary disease","volume":"383","author":"Nidorf","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"26","key":"10.1016\/j.ijcrp.2024.200298_bib17","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and safety of low\u2013dose colchicine after myocardial infarction","volume":"381","author":"Tardif","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"20","key":"10.1016\/j.ijcrp.2024.200298_bib18","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1161\/CIRCULATIONAHA.120.050771","article-title":"Colchicine in patients with acute coronary syndrome","volume":"142","author":"Tong","year":"2020","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.ijcrp.2024.200298_bib19","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1056\/NEJMoa1809798","article-title":"Low\u2013dose methotrexate for the prevention of atherosclerotic events","volume":"380","author":"Ridker","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.ijcrp.2024.200298_bib20","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ijcrp.2024.200298_bib21","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"Rivaroxaban in patients with a recent acute coronary syndrome","volume":"366","author":"Mega","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"14","key":"10.1016\/j.ijcrp.2024.200298_bib22","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"10117","key":"10.1016\/j.ijcrp.2024.200298_bib23","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0140-6736(17)32409-1","article-title":"Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double\u2013blind, placebo\u2013controlled trial","volume":"391","author":"Anand","year":"2018","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.ijcrp.2024.200298_bib24","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa2000052","article-title":"Rivaroxaban in peripheral artery disease after revascularization","volume":"382","author":"Bonaca","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"16","key":"10.1016\/j.ijcrp.2024.200298_bib25","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1056\/NEJMoa060989","article-title":"Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events","volume":"354","author":"Bhatt","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.ijcrp.2024.200298_bib26","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1161\/CIRCULATIONAHA.113.003303","article-title":"Optimal duration of dual antiplatelet therapy after drug\u2013eluting stent implantation","volume":"129","author":"Lee","year":"2014","journal-title":"Circulation"},{"issue":"19","key":"10.1016\/j.ijcrp.2024.200298_bib27","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1056\/NEJMoa1500857","article-title":"Long\u2013term use of ticagrelor in patients with prior myocardial infarction","volume":"372","author":"Bonaca","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"15","key":"10.1016\/j.ijcrp.2024.200298_bib28","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1056\/NEJMoa1001266","article-title":"Duration of dual antiplatelet therapy after implantation of drug\u2013eluting stents","volume":"362","author":"Park","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.ijcrp.2024.200298_bib29","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1001\/jamacardio.2017.5205","article-title":"Associations of omega\u20133 fatty acid supplement use with cardiovascular disease risks","volume":"3","author":"Aung","year":"2018","journal-title":"JAMA Cardiol."},{"issue":"14","key":"10.1016\/j.ijcrp.2024.200298_bib30","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1182\/blood-2010-07-273417","article-title":"Interleukin\u20131 in the pathogenesis and treatment of inflammatory diseases","volume":"117","author":"Dinarello","year":"2011","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.ijcrp.2024.200298_bib31","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C\u2013reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"16","key":"10.1016\/j.ijcrp.2024.200298_bib32","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.021198","article-title":"Colchicine in patients with coronary artery disease: a systematic review and meta\u2010analysis of randomized trials","volume":"10","author":"Kofler","year":"2021","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.ijcrp.2024.200298_bib33","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.740896","article-title":"A meta\u2013analysis evaluating the colchicine therapy in patients with coronary artery disease","volume":"8","author":"Grajek","year":"2021","journal-title":"Front. Cardiovasc. Med."},{"key":"10.1016\/j.ijcrp.2024.200298_bib34","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.608247","article-title":"Low dose rivaroxaban for atherosclerotic cardiovascular diseases: a systematic review and meta\u2013analysis","volume":"11","author":"Chen","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ijcrp.2024.200298_bib35","doi-asserted-by":"crossref","first-page":"7201","DOI":"10.2147\/IJGM.S383485","article-title":"Comparison of aspirin and rivaroxaban plus aspirin in the management of stable coronary artery disease or peripheral artery disease: a systematic review of randomized controlled trials","volume":"15","author":"Debasu","year":"2022","journal-title":"Int. J. Gen. Med."},{"issue":"14","key":"10.1016\/j.ijcrp.2024.200298_bib36","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1161\/CIRCULATIONAHA.119.044598","article-title":"Rivaroxaban plus aspirin versus aspirin alone in patients with prior percutaneous coronary intervention (COMPASS\u2013PCI)","volume":"141","author":"Bainey","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.ijcrp.2024.200298_bib37","doi-asserted-by":"crossref","first-page":"l2222","DOI":"10.1136\/bmj.l2222","article-title":"Duration of dual antiplatelet therapy after percutaneous coronary intervention with drug\u2013eluting stent: systematic review and network meta\u2013analysis","author":"Yin","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.ijcrp.2024.200298_bib38","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.amjcard.2021.04.014","article-title":"Meta\u2013analysis of duration of dual antiplatelet therapy in acute coronary syndrome treated with coronary stenting","volume":"151","author":"Knijnik","year":"2021","journal-title":"Am. J. Cardiol."}],"container-title":["International Journal of Cardiology Cardiovascular Risk and Prevention"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772487524000631?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772487524000631?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T22:44:53Z","timestamp":1732229093000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772487524000631"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":38,"alternative-id":["S2772487524000631"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcrp.2024.200298","relation":{},"ISSN":["2772-4875"],"issn-type":[{"value":"2772-4875","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of drugs in residual cardiovascular risk: A systematic review of the literature","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology Cardiovascular Risk and Prevention","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcrp.2024.200298","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"200298"}}